No Data
No Data
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA (Vibegron) for Men With Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
Japanese Stocks End Flat
Sumitomo Pharma (TSE:4506) Eyes Growth With ORGOVYX Success and Key Alliances Despite Financial Strain
Sumitomo Pharma America and Actor Holly Robinson Peete Encourage People With Overactive Bladder to Speak Up and Seek Treatment
Poxel Announces Results From November 28, 2024 Annual General Meeting
Poxel Announces Availability of the 2023 Universal Registration Document